The Bio-inflammation Company

Transforming Human Health Through The Restoration Of Ammonia-Oxidizing Bacteria

An evolutionary approach to restoring health

AOBiome Therapeutics is a clinical-stage therapeutics company addressing a broad range of inflammatory conditions by harnessing a single strain of class defining
Ammonia Oxidizing Bacteria (AOB).

AOBiome currently has multiple
Phase 2 clinical programs ongoing

AOBiome currently has ongoing Phase 2 clinical programs in hypertension, acne, allergic rhinitis, migraine, eczema and rosacea.


Learn More

Committed to transforming & improving human health

We believe that the restoration of the symbiotic relationship between bacteria and humans
will have a profound impact on human health.


In the News
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine
AOBiome Therapeutics Reports Positive Clinical Safety Results for First-in-Class Microbiome-Targeted Therapy for Intranasal Delivery